Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 11 December 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Recent advances in diagnosis of drug-induced liver injury

The most recent issue of Gut investigated the provision of more advanced scientific and regulatory guidance for safety assessment in drug-induced liver injury.

News image

Idiosyncratic drug-induced liver injury is a rare but potentially severe adverse drug reaction that should be considered in patients who develop laboratory criteria for liver injury secondary to the administration of a potentially hepatotoxic drug. 

Although currently used liver parameters are sensitive in detecting drug-induced liver injury, they are neither specific nor able to predict the patient's subsequent clinical course. 

Genetic risk assessment is useful mainly due to its high negative predictive value, with several human leucocyte antigen alleles being associated with drug-induced liver injury. 

Dr Gerd Kullak-Ublick and colleagues from Switzerland investigated the provision of more advanced scientific and regulatory guidance for liver safety assessment.

A novel drug-induced liver injury cluster score is being developed which predicts drug-induced liver injury
Gut
The team reported that new emerging biomarkers which could be useful in assessing drug-induced liver injury include total keratin18 and caspase-cleaved keratin18, macrophage colony-stimulating factor receptor 1, high mobility group box 1 and microRNA-122. 

From the numerous in vitro test systems that are available, the researchers found that monocyte-derived hepatocytes generated from patients with drug-induced liver injury show promise in identifying the drug-induced liver injury-causing agent from among a panel of coprescribed drugs. 

Several computer-based algorithms are available that rely on cumulative scores of known risk factors such as the administered dose or potential liabilities such as mitochondrial toxicity, inhibition of the bile salt export pump or the formation of reactive metabolites. 

The research team noted that a novel drug-induced liver injury cluster score is being developed which predicts drug-induced liver injury from multiple complimentary cluster and classification models using absorption–distribution–metabolism–elimination-related as well as physicochemical properties, diverse substructural descriptors and known structural liabilities. 

Dr Kullak-Ublick's team comments, "The provision of more advanced scientific and regulatory guidance for liver safety assessment will depend on validating the new diagnostic markers in the ongoing drug-induced liver injury registries, biobanks and public–private partnerships."

Gut 2017;66:1154-1164
25 May 2017

Go to top of page Email this page Email this page to a colleague

 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 05 December 2017 
Childhood obesity into adulthood
 05 December 2017 
CT imaging for acute diverticulitis
 04 December 2017 
Physical activity and Barrett’s esophagus
 04 December 2017 
Alcohol abstinence and alcoholic hepatitis
 04 December 2017 
Neoadjuvant chemoradiation for locally advanced rectal cancer
 01 December 2017 
Insulin therapy and liver cancer among diabetics
 01 December 2017 
Family burden of pediatric Crohn's in the USA
 01 December 2017 
Therapeutic drug monitoring in IBD
 30 November 2017 
Sessile serrated polyps and H. pylori in the USA
 30 November 2017 
Anastomotic leak after repeat intestinal resection in Crohn’s
 30 November 2017 
Oral capsule– vs colonoscopy-delivered fecal microbiota transplant
 29 November 2017 
Medical cannabinoid legalization policy and vomiting
 29 November 2017 
Predicting mortality after colectomy for C. diff
 29 November 2017 
Obesity and cancer risk
 28 November 2017 
Celiac disease screening in adult first-degree relatives
 28 November 2017 
Electronic health record alert in primary care in Hep C
 28 November 2017 
Surgical treatment delays and colon cancer survival
 27 November 2017 
Challenges in measuring the affordability of US health care
 27 November 2017 
Questionnaire fore chronic constipation
 27 November 2017 
Early readmission in IBD patients
 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Predicting microscopic colitis
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Environmental factors and IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us